Loading
PDBj
メニューPDBj@FacebookPDBj@X(formerly Twitter)PDBj@BlueSkyPDBj@YouTubewwPDB FoundationwwPDBDonate
RCSB PDBPDBeBMRBAdv. SearchSearch help

8R12

Structure of compound 8 bound to SARS-CoV-2 main protease

8R12 の概要
エントリーDOI10.2210/pdb8r12/pdb
関連するPDBエントリー8R11
分子名称3C-like proteinase, 2-[[4-(5-chloranylpyridin-3-yl)carbonyl-1,4-diazepan-1-yl]methyl]benzenecarbonitrile, CHLORIDE ION, ... (6 entities in total)
機能のキーワードfragment, inhibitor, protease, hydrolase
由来する生物種Severe acute respiratory syndrome coronavirus 2
タンパク質・核酸の鎖数2
化学式量合計68497.34
構造登録者
Mac Sweeney, A.,Hazemann, J. (登録日: 2023-11-01, 公開日: 2024-02-07, 最終更新日: 2024-07-03)
主引用文献Hazemann, J.,Kimmerlin, T.,Lange, R.,Sweeney, A.M.,Bourquin, G.,Ritz, D.,Czodrowski, P.
Identification of SARS-CoV-2 Mpro inhibitors through deep reinforcement learning for de novo drug design and computational chemistry approaches.
Rsc Med Chem, 15:2146-2159, 2024
Cited by
PubMed Abstract: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has caused a global pandemic of coronavirus disease (COVID-19) since its emergence in December 2019. As of January 2024, there has been over 774 million reported cases and 7 million deaths worldwide. While vaccination efforts have been successful in reducing the severity of the disease and decreasing the transmission rate, the development of effective therapeutics against SARS-CoV-2 remains a critical need. The main protease (Mpro) of SARS-CoV-2 is an essential enzyme required for viral replication and has been identified as a promising target for drug development. In this study, we report the identification of novel Mpro inhibitors, using a combination of deep reinforcement learning for drug design with 3D pharmacophore/shape-based alignment and privileged fragment match count scoring components followed by hit expansions and molecular docking approaches. Our experimentally validated results show that 3 novel series exhibit potent inhibitory activity against SARS-CoV-2 Mpro, with IC values ranging from 1.3 μM to 2.3 μM and a high degree of selectivity. These findings represent promising starting points for the development of new antiviral therapies against COVID-19.
PubMed: 38911172
DOI: 10.1039/d4md00106k
主引用文献が同じPDBエントリー
実験手法
X-RAY DIFFRACTION (1.587 Å)
構造検証レポート
Validation report summary of 8r12
検証レポート(詳細版)ダウンロードをダウンロード

252456

件を2026-04-22に公開中

PDB statisticsPDBj update infoContact PDBjnumon